ScholarIQanswers from OpenAlex & ORCID
Martin Wermke
ResearcherPublications, citations & collaboration network
Martin Wermke is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Martin Wermke have?
ScholarIQindexed works
Martin Wermke has 318 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Martin Wermke have?
ScholarIQcitation count
Martin Wermke has 8,566 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Martin Wermke?
ScholarIQh-index
Martin Wermke has an h-index of 44 in OpenAlex.
What is the i10-index of Martin Wermke?
ScholarIQi10-index
Martin Wermke has an i10-index of 109 in OpenAlex.
What is the ORCID of Martin Wermke?
ScholarIQorcid
The ORCID for Martin Wermke is on the source record.
What is the OpenAlex record for Martin Wermke?
ScholarIQopenalex
The OpenAlex for Martin Wermke is on the source record.
What are the most-cited papers on Martin Wermke?
ScholarIQmost cited works
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Christian Thiede, Christine Steudel, Brigitte Mohr, Markus Schaich, Ulrike Schäkel, Uwe Platzbecker, Martin Wermke, Martin Bornhäuser, Markus Ritter, Andreas Neubauer, Gerhard Ehninger, Thomas Illmer
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
Uwe Platzbecker, Martin Wermke, J. Radke, Uta Oelschlaegel, Franzi Seltmann, Alexander Kiani, I-M Klut, Holger Knoth, Christoph Röllig, Johannes Schetelig, Brigitte Mohr, Xina Graehlert, Gerhard Ehninger, Martin Bornhäuser, Christian Thiede
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
Armin Ehninger, Michael Krämer, Christoph Röllig, Christian Thiede, Martin Bornhäuser, Malte von Bonin, Martin Wermke, Anja Feldmann, Michael Bachmann, Gerhard Ehninger, Uta Oelschlägel, on behalf of the Study Alliance Leukemia
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D. Lewis, Harriet M. Kluger, Omid Hamid, Eric D. Whitman, Sajeve Thomas, Martin Wermke, Mike Cusnir, Evidio Domingo‐Musibay, Giao Q. Phan, John M. Kirkwood, Jessica C. Hassel, Marlana Orloff, James Larkin, Jeffrey S. Weber, Andrew J.S. Furness, Nikhil I. Khushalani, Theresa Medina, Michael E. Egger, Friedrich Graf Finckenstein, Madan Jagasia, Parameswaran Hari, Giri Sulur, Wen Shi, Xiao Wu, Amod A. Sarnaik
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani, John E. Godwin, Martha Arellano, Kendra Sweet, Ashkan Emadi, Farhad Ravandi, Harry P. Erba, Michael Byrne, Laura C. Michaelis, Max S. Topp, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Stefania Paolini, Gerwin Huls, Mojca Jongen‐Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Récher, Patrick J. Stiff, Kristen Pettit, Bob Löwenberg, S. Church, Erica Anderson, Jayakumar Vadakekolathu, Marianne Santaguida, Michael P. Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, Kathy Tran, Patrick Kaminker, Maya Kostova, Ezio Bonvini, Roland B. Walter, Jan Davidson‐Moncada, Sergio Rutella, John F. DiPersio